Martin Show Live Drawing Tutorials

Mary Jul 17, 2026

Martin Shkreli, former chief executive of pharma giant Turing Pharmaceuticals, rose to notoriety in 2015 when his company bought the rights to the drug Daraprim and promptly raised its price by 5,000%, sparking national outrage. While Shkreli has been a polarizing figure, his actions have brought significant attention to the issue of drug pricing in the United States.

The martin lawrence show Martin Lawrence Tattoo, Martin Lawrence Cartoon, Martin Lawrence Show Characters, Martin Lawrence Memes, Bernie Mac Drawing, Martin Tv Show Art, Martin Lawrence Logo, Martin Lawrence Characters, Martin Lawrence Otis
The martin lawrence show Martin Lawrence Tattoo, Martin Lawrence Cartoon, Martin Lawrence Show Characters, Martin Lawrence Memes, Bernie Mac Drawing, Martin Tv Show Art, Martin Lawrence Logo, Martin Lawrence Characters, Martin Lawrence Otis

Shkreli, dubbed the "Most Hated Man in America" during this period, became the face of big pharma's greed and sparked a national conversation about drug affordability. His actions led to numerous investigations, congressional hearings, and ultimately, a federal trial that convicted him on securities fraud charges unrelated to the drug pricing scandal.

Martin drawing
Martin drawing

Martin Shkreli's Background

Born in 1982, Shkreli grew up in a working-class family in Brooklyn, New York. He graduated from Baruch College and began his career as a hedge fund manager, founding his first hedge fund, Elea Pharmaceuticals, in 2011.

Martin sketch ⋆
Martin sketch ⋆

In 2014, Shkreli founded Turing Pharmaceuticals with the goal of developing new treatments for rare diseases. However, it was his decision to acquire Daraprim in 2015 that brought him unwanted fame and infamy.

Daraprim Pricing Controversy

Martin draw
Martin draw

Daraprim, a drug used to treat a rare parasitic infection, had been on the market for over 60 years with a price tag of $13.50 per pill. When Turing Pharmaceuticals acquired the drug, Shkreli raised the price to $750 per pill, an increase of 4,985%.

This astronomical price increase sparked widespread outrage, with critics accusing Shkreli and Turing of price gouging. The decision gained significant media attention, with Shkreli's actions sparking nationwide protests and earning him the moniker "Pharma Bro." Shkreli initially defended the price increase, stating that Turing would increase profits and use them to develop new drugs.

Legal Consequences

martin… again
martin… again

In December 2015, following a congressional hearing where Shkreliöffentlichungen Republiken and Democrats alike criticized his actions, the U.S. government launched a civil enforcement action against Turing Pharmaceuticals for allegedly misled investors about the effects of Daraprim's price increase on the company's stock price.

The legal fallout from Shkreli's actions extended beyond the Daraprim controversy. In 2017, Shkreli was found guilty on two counts of securities fraud and one count of conspiracy to commit securities fraud, unrelated to his actions at Turing. He was sentenced to seven years in prison and ordered to pay a $7.36 million fine.

Shkreli's Legacy and Impact on Drug Pricing

— martin • fanart
— martin • fanart

Despite his controversial actions and subsequent legal troubles, Martin Shkreli has left an indelible mark on the national conversation about drug pricing in the United States. His actions in raising the price of Daraprim brought significant attention to the issue of drug affordability and sparked numerous debates and investigations into the pharmaceutical industry's pricing practices.

The public outrage that followed Shkreli's decision to raise the price of Daraprim also led to legislative action. In 2018, the federal government passed the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, which includes measures designed to increase drug pricing transparency and encourage competition in the generic drug market.

» martin ; play that beat
» martin ; play that beat
— martin • fanart
— martin • fanart
My drawing of Martin
My drawing of Martin
Martin, Y so fine ‼️💥😔
Martin, Y so fine ‼️💥😔
three different colored drawings of people with faces and hands, one has his mouth open
three different colored drawings of people with faces and hands, one has his mouth open
Martin from Cortis
Martin from Cortis
Martin ( cortis) fanart 🦒
Martin ( cortis) fanart 🦒
an image of cartoon characters from the tv series martin and other people with different facial expressions
an image of cartoon characters from the tv series martin and other people with different facial expressions
Martin
Martin

The Role of "Pharma Bro" in sparking change

The image of "Pharma Bro" as a ruthless and greedy businessman has become a powerful symbol in the ongoing debate over drug pricing. His actions and subsequent notoriety have galvanized both public and legislative initiatives aimed at reining in drug prices and increasing affordability for patients.

In the years since the Daraprim pricing controversy, numerous other pharmaceutical companies have been accused of engaging in similar practices, underscoring the need for continued vigilance and action on the part of consumers, lawmakers, and industry regulators. As the debate over drug pricing continues to evolve, the legacy of "Pharma Bro" serves as a stark reminder of the importance of holding pharmaceutical companies accountable for their pricing practices.

As for Martin Shkreli himself, his notoriety and subsequent legal troubles have ensured that his name will be forever linked with the ongoing debate over drug pricing. While his actions may have been driven by personal gain, they have also played an ironic role in spurring efforts to increase drug affordability and transparency. As the pharmaceutical industry continues to evolve, thehope for many is that Shkreli's example serves as a catalyst for positive change.